Fluoroestradiol F-18
- Generic Name
- Fluoroestradiol F-18
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H23FO2
- CAS Number
- 94153-53-4
- Unique Ingredient Identifier
- T32277KB09
- Background
Fluoroestradiol F-18 is an imaging agent used with positron emission tomography (PET) to detect estrogen receptor-positive breast cancer lesions. The ability to image ER-positive tumors in vivo is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression across metastases (...
- Indication
Fluoroestradiol F-18 is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
- Associated Conditions
- Metastatic Estrogen Receptor Positive Breast Cancer, Recurrent Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- -
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT06260033
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2
- Registration Number
- NCT04692103
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Annie (Annie) T. Packard
- Registration Number
- NCT04347135
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
- Conditions
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 13
- Registration Number
- NCT03703492
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 99
- Registration Number
- NCT02398773
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02374931
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT02149173
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.